Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel

Molecular and Cellular Endocrinology

Volumn 363, Issue 1-2, 2012, Pages 111-121

  Schlaepfer, Isabel R ^a   Hitz, Carolyn A ^a   Gijón, Miguel A ^b   Bergman, Bryan C ^a   Eckel, Robert H ^a   Jacobsen, Britta M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Breast cancer; Docetaxel; Lipid droplets; Metabolism; Progestin; SCD 1

Indexed keywords

ACYL COENZYME A DESATURASE; DOCETAXEL; FAT DROPLET; GLUCOSE; MEDROXYPROGESTERONE ACETATE; OLEIC ACID; PHOSPHOLIPID; PROGESTERONE RECEPTOR; UNSATURATED FATTY ACID;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL MEMBRANE FLUIDITY; CELL PROTECTION; CELL STRAIN MDA MB 231; CELL STRAIN T47D; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIPID STORAGE; LIPOGENESIS; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FATTY ACIDS, NONESTERIFIED; FEMALE; GENE EXPRESSION; GLUCOSE; GONANES; HUMANS; LIPOGENESIS; MEDROXYPROGESTERONE ACETATE; PHOSPHOLIPIDS; PROGESTINS; RECEPTORS, PROGESTERONE; STEAROYL-COA DESATURASE; TAXOIDS; TRIGLYCERIDES;

EID: 84866919872     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.08.005     Document Type: Article

References (67)

1. Badtke M.M., Jambal P., Dye W.W., Spillman M.A., Post M.D., Horwitz K.B., Jacobsen B.M. Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Breast Cancer Res. Treat. 2012, 131:75-87.
2. Baritaki S., Apostolakis S., Kanellou P., Dimanche-Boitrel M.T., Spandidos D.A., Bonavida B. Reversal of tumor resistance to apoptotic stimuli by alteration of membrane fluidity: therapeutic implications. Adv. Cancer Res. 2007, 98:149-190.
3. Bayet-Robert M., Morvan D., Chollet P., Barthomeuf C. Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res Treat. 2009, 120:613-626.
4. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
5. Chajes V., Hulten K., Van Kappel A.L., Winkvist A., Kaaks R., Hallmans G., Lenner P., Riboli E. Fatty-acid composition in serum phospholipids and risk of breast cancer: an incident case-control study in Sweden. Int. J. Cancer 1999, 83:585-590.
6. Chalbos D., Chambon M., Ailhaud G., Rochefort H. Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J. Biol. Chem. 1987, 262:9923-9926.
7. Chalbos D., Joyeux C., Galtier F., Escot C., Chambon M., Maudelonde T., Rochefort H. Regulation of fatty acid synthetase by progesterone in normal and tumoral human mammary glands. Rev. Esp. Fisiol. 1990, 46:43-46.
8. Chalbos D., Rochefort H. A 250-kilodalton cellular protein is induced by progestins in two human breast cancer cell lines MCF7 and T47D. Biochem. Biophys. Res. Commun. 1984, 121:421-427.
9. Chalbos D., Vignon F., Keydar I., Rochefort H. Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J. Clin. Endocrinol. Metab. 1982, 55:276-283.
10. Chlebowski R.T., Anderson G.L., Gass M., Lane D.S., Aragaki A.K., Kuller L.H., Manson J.E., Stefanick M.L., Ockene J., Sarto G.E., Johnson K.C., Wactawski-Wende J., Ravdin P.M., Schenken R., Hendrix S.L., Rajkovic A., Rohan T.E., Yasmeen S., Prentice R.L. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692.
11. Classen S., Possinger K., Pelka-Fleischer R., Wilmanns W. Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J. Steroid Biochem. Mol. Biol. 1993, 45:315-319.
12. Corona G., Elia C., Casetta B., Frustaci S., Toffoli G. High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry. Clin. Chim. Acta 2011, 412:358-364.
13. Ghatge R.P., Jacobsen B.M., Schittone S.A., Horwitz K.B. The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res. 2005, 7:R1036-R1050.
14. Groshong S.D., Owen G.I., Grimison B., Schauer I.E., Todd M.C., Langan T.A., Sclafani R.A., Lange C.A., Horwitz K.B. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol. Endocrinol. 1997, 11:1593-1607.
15. Hardy S., Langelier Y., Prentki M. Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Res. 2000, 60:6353-6358.
16. Hardy S., St Onge G.G., Joly E., Langelier Y., Prentki M. Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. J. Biol. Chem. 2005, 280:13285-13291.
17. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., Ingle J.N., Cooper M.R., Hayes D.F., Tkaczuk K.H., Fleming G., Holland J.F., Duggan D.B., Carpenter J.T., Frei E., Schilsky R.L., Wood W.C., Muss H.B., Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. 2003, 21:976-983.
18. Horwitz K.B., Dye W.W., Harrell J.C., Kabos P., Sartorius C.A. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc. Natl. Acad. Sci. USA. 2008, 105:5774-5779.
19. Horwitz K.B., Wei L.L., Sedlacek S.M., d'Arville C.N. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog. Horm. Res. 1985, 41:249-316.
20. Ito H., Kasama K., Naruse S., Shimura K. Antitumor effect of palmitoleic acid on Ehrlich ascites tumor. Cancer Lett. 1982, 17:197-203.
21. Ito K., Utsunomiya H., Niikura H., Yaegashi N., Sasano H. Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer. Mol Cell Endocrinol. 2010, 340:161-167.
22. Judge S.M., Chatterton R.T. Progesterone-specific stimulation of triglyceride biosynthesis in a breast cancer cell line (T-47D). Cancer Res. 1983, 43:4407-4412.
23. Kalkhoff R.K. Metabolic effects of progesterone. Am. J. Obstet. Gynecol. 1982, 142:735-738.
24. Kaluzny M.A., Duncan L.A., Merritt M.V., Epps D.E. Rapid separation of lipid classes in high yield and purity using bonded phase columns. J. Lipid Res. 1985, 26:135-140.
25. Keen J.C., Davidson N.E. The biology of breast carcinoma. Cancer 2003, 97:825-833.
26. Koopman R., Schaart G., Hesselink M.K. Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem. Cell Biol. 2001, 116:63-68.
27. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006, 66:5977-5980.
28. Kusakabe T., Maeda M., Hoshi N., Sugino T., Watanabe K., Fukuda T., Suzuki T. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J. Histochem. Cytochem. 2000, 48:613-622.
29. Lange C.A. Challenges to defining a role for progesterone in breast cancer. Steroids 2008, 73:914-921.
30. Lin V.C., Ng E.H., Aw S.E., Tan M.G., Ng E.H., Chan V.S., Ho G.H. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin. Cancer Res. 1999, 5:395-403.
31. Liu H., Liu Y., Zhang J.T. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol. Cancer Ther. 2008, 7:263-270.
32. Lyons T.R., Schedin P.J., Borges V.F. Pregnancy and breast cancer: when they collide. J. Mammary Gland Biol. Neoplasia 2009, 14:87-98.
33. Lyseng-Williamson K.A., Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005, 65:2513-2531.
34. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 2009, 100:1369-1372.
35. Medina R.A., Meneses A.M., Vera J.C., Guzman C., Nualart F., Astuya A., Garcia M.A., Kato S., Carvajal A., Pinto M., Owen G.I. Estrogen and progesterone up-regulate glucose transporter expression in ZR-75-1 human breast cancer cells. Endocrinology 2003, 144:4527-4535.
36. Medina R.A., Owen G.I. Glucose transporters: expression, regulation and cancer. Biol. Res. 2002, 35:9-26.
37. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
38. Menendez J.A., Vellon L., Colomer R., Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int. J. Cancer 2005, 115:19-35.
39. Meyer W.J., Walker P.A., Emory L.E., Smith E.R. Physical, metabolic, and hormonal effects on men of long-term therapy with medroxyprogesterone acetate. Fertil. Steril. 1985, 43:102-109.
40. Montopoli M., Bellanda M., Lonardoni F., Ragazzi E., Dorigo P., Froldi G., Mammi S., Caparrotta L. " Metabolic reprogramming" in ovarian cancer cells resistant to Cisplatin. Curr. Cancer Drug Targets 2011, 11:226-235.
41. Moore M.R., Conover J.L., Franks K.M. Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells. Biochem. Biophys. Res. Commun. 2000, 277:650-654.
42. Moore M.R., Spence J.B., Kiningham K.K., Dillon J.L. Progestin inhibition of cell death in human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 2006, 98:218-227.
43. Musgrove E.A., Lee C.S., Sutherland R.L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell. Biol. 1991, 11:5032-5043.
44. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002, 288:872-881.
45. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S., Gazdar A., Gray J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
46. Nomura D.K., Long J.Z., Niessen S., Hoover H.S., Ng S.W., Cravatt B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140:49-61.
47. Ory K., Lebeau J., Levalois C., Bishay K., Fouchet P., Allemand I., Therwath A., Chevillard S. Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines. Breast Cancer Res. Treat. 2001, 68:187-198.
48. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
49. Picard F., Wanatabe M., Schoonjans K., Lydon J., O'Malley B.W., Auwerx J. Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta-cell proliferation. Proc. Natl. Acad. Sci. USA 2002, 99:15644-15648.
50. Przybytkowski E., Joly E., Nolan C.J., Hardy S., Francoeur A.M., Langelier Y., Prentki M. Upregulation of cellular triacylglycerol - free fatty acid cycling by oleate is associated with long-term serum-free survival of human breast cancer cells. Biochem. Cell Biol. 2007, 85:301-310.
51. Rochon C., Prod'homme M., Laurichesse H., Tauveron I., Balage M., Gourdon F., Baud O., Jacomet C., Jouvency S., Bayle G., Champredon C., Thieblot P., Beytout J., Grizard J. Effect of medroxyprogesterone acetate on the efficiency of an oral protein-rich nutritional support in HIV-infected patients. Reprod. Nutr. Dev. 2003, 43:203-214.
52. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
53. Sarabia V., Lam L., Burdett E., Leiter L.A., Klip A. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J. Clin. Invest. 1992, 90:1386-1395.
54. Sartorius C.A., Groshong S.D., Miller L.A., Powell R.L., Tung L., Takimoto G.S., Horwitz K.B. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res. 1994, 54:3868-3877.
55. Sartorius C.A., Harvell D.M., Shen T., Horwitz K.B. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res. 2005, 65:9779-9788.
56. Scaglia N., Chisholm J.W., Igal R.A. Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: role of AMPK. PLoS ONE 2009, 4:e6812.
57. Scarpin K.M., Graham J.D., Mote P.A., Clarke C.L. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl. Recept. Signal. 2009, 7:e009.
58. Schedin P.J., Watson C.J. The complexity of the relationships between age at first birth and breast cancer incidence curves implicate pregnancy in cancer initiation as well as promotion of existing lesions. Preface. J. Mammary Gland Biol. Neoplasia 2009, 14:85-86.
59. Schmidt M., Bremer E., Hasenclever D., Victor A., Gehrmann M., Steiner E., Schiffer I.B., Gebhardt S., Lehr H.A., Mahlke M., Hermes M., Mustea A., Tanner B., Koelbl H., Pilch H., Hengstler J.G. Role of the progesterone receptor for paclitaxel resistance in primary breast cancer. Br. J. Cancer 2007, 96:241-247.
60. Shirling D., Ashby J.P., Baird J.D. Effect of progesterone on lipid metabolism in the intact rat. J. Endocrinol. 1981, 90:285-294.
61. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein L.P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
62. Szutowicz A., Kwiatkowski J., Angielski S. Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br. J. Cancer 1979, 39:681-687.
63. Taylor R.S., Jones S.M., Dahl R.H., Nordeen M.H., Howell K.E. Characterization of the Golgi complex cleared of proteins in transit and examination of calcium uptake activities. Mol. Biol. Cell 1997, 8:1911-1931.
64. Tuttle S., Turkington V.E. Effects of medroxyprogesterone acetate on carbohydrate metabolism. Obstet. Gynecol. 1974, 43:685-692.
65. Urien S., Barre J., Morin C., Paccaly A., Montay G., Tillement J.P. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest. New Drugs 1996, 14:147-151.
66. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
67. Zeng L., Biernacka K.M., Holly J.M., Jarrett C., Morrison A.A., Morgan A., Winters Z.E., Foulstone E.J., Shield J.P., Perks C.M. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr. Relat. Cancer 2010, 17:539-551.